Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

  • Carmona, F. David
  • Coit, Patrick
  • Saruhan-Direskeneli, Güher
  • Hernández-Rodríguez, José
  • Cid, María C.
  • Solans Laque, Roser
Estudis d'associació de genoma; Síndromes de vasculitis, Estudios de asociación de genoma; Síndromes de vasculitis, Genome-wide association studies; Vasculitis syndromes, Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; ORGCA = 1.19, ORTAK = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (PGCA = 5.52E-04, ORGCA = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus., This work was supported by SAF2012–34435 from the Spanish Ministry of Economy and Competitiveness, BIO-1395 from Junta de Andalucía, and RD12/0009/0004 from the RETICS Program (RIER) of Instituto de Salud Carlos III (ISCIII). FDC was recipient of a grant from the ‘Ramón y Cajal’ programme of the Spanish Ministry of Economy and Competitiveness (RYC-2014–16458). MCC and JHR are supported by Ministerio de Economía y Competitividad (SAF 14/57708R), cofunded by “Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa” [Instituto de Salud Carlos III and Fondo Europeo de desarrollo regional (FEDER) (PIE 13/00033)]. The Vasculitis Clinical Research Consortium has received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network (RDCRN).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor, Experience from an academic phase i clinical trial

  • Castellà, Maria
  • Caballero-Baños, M.
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Boronat Barado, Anna
  • Marzal, Berta
  • Millán, Lucía
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Lozano, Miquel|||0000-0003-2593-833X
  • García, E.
  • Tabera, Jaime|||0000-0002-5430-0151
  • Trias, E.
  • Perpiña, U.
  • Canals, Josep M.|||0000-0001-6829-7670
  • Baumann, Tycho|||0000-0003-4421-0088
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Campo, Elias|||0000-0001-9850-9793
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Rives, S.
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in academic institutions. However, the feasibility of manufacturing CAR T-cell products from heavily pre-treated patients with this system has not been demonstrated yet. Here we report and characterize the production of 28 CAR T-cell products in the context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full list of specifications and were considered valid products. Ex vivo cell expansion lasted an average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products obtained presented cytotoxic activity against CD19+ cells and were proficient in the secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient's cells compared to healthy donor's cells. However, product potency was comparable. CAR T-cell subset phenotype was highly variable among patients and largely determined by the initial product. T and T were the predominant T-cell phenotypes obtained. 38.7% of CAR T-cells obtained presented a TN or T phenotype, in average, which are the subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth analysis to identify individual factors contributing to the optimal T-cell phenotype revealed that ex vivo cell expansion leads to reduced numbers of T, T, and T cells, while T cells increase, both due to cell expansion and CAR-expression. Overall, our results show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated patients using CliniMACS Prodigy system is feasible, and that the obtained products meet the current quality standards of the field. Reduced ex vivo expansion may yield CAR T-cell products with increased persistence in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

  • Carmona, F. David|||0000-0002-1427-7639
  • Coit, Patrick
  • Saruhan-Direskeneli, Güher
  • Hernández Rodríguez, José|||0000-0002-2357-2015
  • Cid, María Cinta|||0000-0002-4730-0938
  • Solans, Roser|||0000-0002-0058-1293
  • Castañeda, Santos|||0000-0002-7748-853X
  • Vaglio, Augusto
  • Direskeneli, Haner
  • Merkel, Peter A.|||0000-0001-9284-7345
  • Boiardi, Luigi
  • Salvarani, Carlo|||0000-0001-5426-5133
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Martín, Javier|||0000-0002-2202-0622
  • Sawalha, Amr H.
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1 / HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; OR = 1.19, OR = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (P = 5.52E-04, OR = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of a Novel Anti-CD19 Chimeric Antigen Receptor, A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

  • Castellà, Maria
  • Boronat, Anna|||0000-0003-0852-3634
  • Martín-Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Caballero Baños, Miguel|||0000-0002-2313-7988
  • Marzal, Berta
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Bueno, Clara|||0000-0003-1442-6216
  • Balagué, Olga|||0000-0002-5099-3675
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Serra-Pages, Carles
  • Engel, Pablo|||0000-0001-8410-252X
  • Vilella, Ramon
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Cid, Joan|||0000-0001-5445-4508
  • Tabera, Jaime|||0000-0002-5430-0151
  • Canals, Josep M.|||0000-0001-6829-7670
  • Lozano, Miquel|||0000-0003-2593-833X
  • Baumann, Tycho|||0000-0003-4421-0088
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Trias, Esteve|||0000-0001-7635-4428
  • Campo, Elias|||0000-0001-9850-9793
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Rives, Susana|||0000-0002-5658-1831
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdc Il2rd/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells

  • Body, Simon
  • Esteve-Arenys, Anna
  • Miloudi, Hadjer
  • Recasens-Zorzo, C.lara
  • Tchakarska, Guergana
  • Moros, Alexandra
  • Bustany, Sophie
  • Vidal-Crespo, Anna
  • Rodriguez, Vanina
  • Lavigne, Régis
  • Com, Emmanuelle
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Weigert, Oliver
  • Sanjuan-Pla, Alejandra
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Marcq, Bénédicte
  • Picquenot, Jean-Michel
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Jardin, Fabrice
  • Roué, Gaël|||0000-0003-0245-2257
  • Sola, Brigitte|||0000-0001-7278-9651
Mantle cell lymphoma (MCL) is a hematologic neoplasm characterised by the t(11;14)(q13;q32) translocation leading to aberrant cyclin D1 expression. The cell functions of cyclin D1 depend on its partners and/or subcellular distribution, resulting in different oncogenic properties. We observed the accumulation of cyclin D1 in the cytoplasm of a subset of MCL cell lines and primary cells. In primary cells, this cytoplasmic distribution was correlated with a more frequent blastoid phenotype. We performed immunoprecipitation assays and mass spectrometry on enriched cytosolic fractions from two cell lines. The cyclin D1 interactome was found to include several factors involved in adhesion, migration and invasion. We found that the accumulation of cyclin D1 in the cytoplasm was associated with higher levels of migration and invasiveness. We also showed that MCL cells with high cytoplasmic levels of cyclin D1 engrafted more rapidly into the bone marrow, spleen, and brain in immunodeficient mice. Both migration and invasion processes, both in vivo and in vitro, were counteracted by the exportin 1 inhibitor KPT-330, which retains cyclin D1 in the nucleus. Our data reveal a role of cytoplasmic cyclin D1 in the control of MCL cell migration and invasion, and as a true operator of MCL pathogenesis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

  • Carmona, F. David
  • Coit, Patrick
  • Saruhan-Direskeneli, Güher
  • Hernández-Rodríguez, José
  • Cid, María C.
  • Solans Laque, Roser
Estudis d'associació de genoma; Síndromes de vasculitis, Estudios de asociación de genoma; Síndromes de vasculitis, Genome-wide association studies; Vasculitis syndromes, Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; ORGCA = 1.19, ORTAK = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (PGCA = 5.52E-04, ORGCA = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus., This work was supported by SAF2012–34435 from the Spanish Ministry of Economy and Competitiveness, BIO-1395 from Junta de Andalucía, and RD12/0009/0004 from the RETICS Program (RIER) of Instituto de Salud Carlos III (ISCIII). FDC was recipient of a grant from the ‘Ramón y Cajal’ programme of the Spanish Ministry of Economy and Competitiveness (RYC-2014–16458). MCC and JHR are supported by Ministerio de Economía y Competitividad (SAF 14/57708R), cofunded by “Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa” [Instituto de Salud Carlos III and Fondo Europeo de desarrollo regional (FEDER) (PIE 13/00033)]. The Vasculitis Clinical Research Consortium has received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the National Center for Research Resources (U54 RR019497), the Office of Rare Diseases Research, and the National Center for Advancing Translational Science. The VCRC is part of the Rare Diseases Clinical Research Network (RDCRN).